Status and phase
Conditions
Treatments
About
The purpose of this study is to evaluate the efficacy of Durvalumab plus Regorafenib versus observation for patients with stage IV colorectal cancer achieving the no evidence of disease state.
The NED state can be achieved in any line of treatment and it is defined as:
Participants in this study will receive:
Experimental arm:
Regorafenib 90 mg d1-21 every 28 days plus Durvalumab 1500 mg every 28 days for 1 year
Control arm:
Observation (crossover to Experimental arm is allowed in case of relapse)
Tumor assessment will be performed every 12 weeks.
Full description
The safety run-in phase is planned for the first 4 patients randomized to the experimental arm using a starting dose of 60 mg/die of Regorafenib (and fixed 1500 mg of Durvalumab), to be escalated after 2 months to 90 mg/die if < 2 patients report serious adverse events.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
182 participants in 2 patient groups
Loading...
Central trial contact
Alberto Sobrero, MD; Alessandro Pastorino, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal